

USPTO PATENT FULL-TEXT AND IMAGE DATABASE

Home	Quick	Advanced	Pat Num	Help
	Hit List	Next	Bottom	
	View Cart	Add to Cart		
	Images			

(1 of 30)

United States Patent
Fernandez-Pol

6,441,009
 August 27, 2002

Agent and method of preventing and treating heavy metal exposure and toxicity

Abstract

An agent and method for the prevention and treatment of toxicity caused by heavy metals such as depleted uranium, tungsten and nickel and metals such as iron, lead and copper. The agent is a chelating agent such as picolinic acid or derivatives thereof. The agent chelates and inactivates the metals which can be carcinogenic or poisonous. The agent can be administered to chelate excessive copper as a result of Wilson's disease. The agent can be administered orally or by other systemic routes such as injections and the like.

Inventors: Fernandez-Pol; Jose A. (Chesterfield, MO)

Assignee: Novactyl, Inc. (St. Louis, MO)

Appl. No.: 676911

Filed: October 2, 2000

Current U.S. Class:

514/354; 514/13; 514/355; 514/356

Intern'l Class:

A61K 031/44; A61K 038/10

Field of Search:

514/354,355,356,13

References Cited [Referenced By]U.S. Patent Documents

<u>3903285</u>	Sep., 1975	Umezawa et al.	
<u>4044140</u>	Aug., 1977	Sherlock.	
<u>4120762</u>	Oct., 1978	Sviokla.	
<u>4138488</u>	Feb., 1979	Sherlock et al.	424/250.
<u>4139625</u>	Feb., 1979	Sherlock	424/266.
<u>4293547</u>	Oct., 1981	Lewis et al.	
<u>4443459</u>	Apr., 1984	Yano et al.	
<u>4814351</u>	Mar., 1989	Mathews et al.	
<u>5057320</u>	Oct., 1991	Evans et al.	

Aulakh, Charanjit S.
Primary Examiner
United States Patent and Trademark Office
Commissioner of Patents and Trademarks
Washington, DC 20231

Reference:


1. Fernandez-Pol, USA patent 6,441,009, August 27, 2002. Agent and method of preventing and treating heavy metal exposure and toxicity.

Subject: AUTHORSHIP RESPONSIBILITY

Dear Examiner: Aulakh, Charanjit S.:

By signing this document, I certify that I have not participated sufficiently in the conception and design of this work, the analysis of the data (where applicable) as well as in the writing of the patents, to take public responsibility for it. I cannot warrant that the patents represent valid original work, since I have not even seen a substantial portion of the data presented. I have reviewed the original version of the patent and did not approve its submission without the necessary corrections. Neither this patent nor others with similar content under my authorship should be published without the correction of errors that I indicated in writing to both Novactyl's patent attorneys and to the Board of Directors. Furthermore, I attest that a portion of the data on which the patents are based have never been shown to me by the management. Thus, the management has to produce the data on which this patent is based. The undersign cannot warrant that the patents contain no libelous or unlawful statements, that they do not infringe on the rights of others, or contain material or instructions that might cause harm or injury, particularly in reference to patient treatments which represent cases introduced by the management.

Sincerely,



Jose A. Fernandez-Pol, M.D.
437 Hunters Hill Dr.
Chesterfield, MO 63917-3446

TE: 314-275-7856

P.S.: The management at the time of patent application and prosecution of the patents indicated above were: Michael Douglas, Ph.D., Vice President & Chief Scientific Officer, Mr. Raymond Zipprich, Vice President, Chief Operating Officer & Chief Financial Officer, and Avinash Amin, M.D., Vice President, Clinical Affairs.

Novactyl, Inc
1816 Lackland Hill Parkway, Suite 220
St. Louis, Missouri 63146
Telephone: 314-991-3890
e-mail: zipprich@Novactyl.com